Literature DB >> 26687141

Pulmonary Artery Pressure and Benefit of Lung Transplantation in Adult Cystic Fibrosis Patients.

Don Hayes1, Dmitry Tumin2, Curt J Daniels3, Karen S McCoy4, Heidi M Mansour5, Joseph D Tobias6, Stephen E Kirkby7.   

Abstract

BACKGROUND: The effect of lung transplantation (LTx) in patients afflicted with cystic fibrosis (CF) and pulmonary hypertension (PH) at placement on the waiting list is not well studied.
METHODS: To predict the relationship between initial mean pulmonary artery pressure (MPAP) and hazard ratio (HR) of death after listing associated with LTx in adult patients with CF, the United Network for Organ Sharing database was queried for the years 2005 to 2013. Survival was assessed from waiting list entry until death on the waiting list, death after LTx, or censoring. A multivariate Cox model was performed to estimate the HR of LTx conditional on MPAP at listing.
RESULTS: Of 1,841 patients with CF, 10% (177) died on the waiting list, 18% (325) were censored without undergoing LTx, and 73% (1,339) underwent transplantation, 361 of whom died after transplantation. A multivariate Cox model of survival since list entry including 1,336 patients found a protective but statistically insignificant benefit of LTx for patients whose MPAP at listing was 25 mm Hg (HR, 0.879; 95% confidence interval [CI], 0.657-1.177; p = 0.388), yet LTx was predicted to be more protective at higher initial MPAP levels, as indicated by the significant interaction term between LTx and MPAP (HR, 0.953; 95% CI, 0.928-0.978; p < 0.001). The predicted LTx HR and 95% CI were protective (HR < 1) at p < 0.05 for patients with MPAP greater than or equal to 30 mm Hg at listing.
CONCLUSIONS: Survival benefit of LTx in CF was increasingly protective at higher MPAP levels, with a severity level of PH established above which a survival advantage of LTx was found.
Copyright © 2016 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26687141     DOI: 10.1016/j.athoracsur.2015.09.086

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Impact of Donor Arterial Partial Pressure of Oxygen on Outcomes After Lung Transplantation in Adult Cystic Fibrosis Recipients.

Authors:  Don Hayes; Benjamin T Kopp; Stephen E Kirkby; Susan D Reynolds; Heidi M Mansour; Joseph D Tobias; Dmitry Tumin
Journal:  Lung       Date:  2016-06-08       Impact factor: 2.584

Review 2.  Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines.

Authors:  Kathleen J Ramos; Patrick J Smith; Edward F McKone; Joseph M Pilewski; Amy Lucy; Sarah E Hempstead; Erin Tallarico; Albert Faro; Daniel B Rosenbluth; Alice L Gray; Jordan M Dunitz
Journal:  J Cyst Fibros       Date:  2019-03-27       Impact factor: 5.482

3.  Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.

Authors:  Lorriana E Leard; Are M Holm; Maryam Valapour; Allan R Glanville; Sandeep Attawar; Meghan Aversa; Silvia V Campos; Lillian M Christon; Marcelo Cypel; Göran Dellgren; Matthew G Hartwig; Siddhartha G Kapnadak; Nicholas A Kolaitis; Robert M Kotloff; Caroline M Patterson; Oksana A Shlobin; Patrick J Smith; Amparo Solé; Melinda Solomon; David Weill; Marlies S Wijsenbeek; Brigitte W M Willemse; Selim M Arcasoy; Kathleen J Ramos
Journal:  J Heart Lung Transplant       Date:  2021-07-24       Impact factor: 13.569

4.  Increased Mortality in Adult Cystic Fibrosis Patients with Medicaid Insurance Awaiting Lung Transplantation.

Authors:  Katelyn Krivchenia; Dmitry Tumin; Joseph D Tobias; Don Hayes
Journal:  Lung       Date:  2016-08-10       Impact factor: 2.584

5.  Pulmonary artery enlargement is associated with pulmonary hypertension and decreased survival in severe cystic fibrosis: A cohort study.

Authors:  Aline N Zouk; Swati Gulati; Dongqi Xing; Keith M Wille; Steven M Rowe; J Michael Wells
Journal:  PLoS One       Date:  2020-02-20       Impact factor: 3.240

6.  Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization, in vitro 2D/3D human lung cell cultures, and in vivo efficacy.

Authors:  Maria F Acosta; Priya Muralidharan; Carissa L Grijalva; Michael D Abrahamson; Don Hayes; Jeffrey R Fineman; Stephen M Black; Heidi M Mansour
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 5.158

7.  Inhalable Nanoparticles/Microparticles of an AMPK and Nrf2 Activator for Targeted Pulmonary Drug Delivery as Dry Powder Inhalers.

Authors:  Maria F Acosta; Michael D Abrahamson; David Encinas-Basurto; Jeffrey R Fineman; Stephen M Black; Heidi M Mansour
Journal:  AAPS J       Date:  2020-11-16       Impact factor: 3.603

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.